Secondary Logo

Institutional members access full text with Ovid®

New perspectives in the therapeutic approach of peripheral T-cell lymphoma

Gisselbrecht, Christiana; Sibon, Davidb

doi: 10.1097/CCO.0000000000000469
LYMPHOMA: Edited by Dominique Bron

Purpose of review Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell and natural killer (NK)-cell neoplasms in the WHO 2016 classification. Patient prognosis is poor when treated with CHOP, and there is an unmet need for new drugs. Several agents have been developed for PTCL, and their use is the subject of this review.

Recent findings Phase 2 studies demonstrated the activity of new drugs in Relapsed/refractory PTCL. Only four compounds were approved by the food and drug administration: romidepsin and belinostat, which are epigenetic modifiers, the antifolate agent pralatrexate, the immuno-conjugate brentuximab vedotin. New combinations have been tested, but the results were disappointing. Given the latest progress in biology, targeted agents are evaluated in different subtypes of PTCL. Relapsed anaplastic large-cell lymphoma exhibits improved prognosis with the approved anti-CD30 drug conjugate brentuximab vedotin. Localized nasal NK/T is treated with radiotherapy and nonanthracycline chemotherapy with L-asparaginase. Recently, immune checkpoint inhibitors demonstrated activity in NK/T lymphoma and can be used in elderly patients.

Summary Treatment remains a challenge for PTCL, and several targeted drugs provide new approaches. Progress will be made incrementally in the different subtypes. One of the critical situations facing new drugs is the ability to run robust clinical trials in rare diseases.

aHôpital Saint Louis, Institut d’hématologie Paris Diderot University

bHematology Department, Necker University Hospital, AP–HP, Paris Descartes University – Sorbonne Paris Cité, Paris, France

Correspondence to Christian Gisselbrecht, MD, Hôpital Saint Louis, Institut d’hématologie Paris Diderot University, 1, avenue Claude Vellefaux, 75010 Paris, France. Tel: +33 6 82 11 05 06; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.